AI-Supported Hybrid Closed Loop System AIDANET for Type 1 Diabetes
Summary
NLM registered a clinical study on ClinicalTrials.gov evaluating an AI-supported hybrid closed loop system (AIDANET) for automated glucose management in adults with Type 1 diabetes. The single-arm study will assess system safety and effectiveness over a 12-week period using CGM metrics and HbA1c measurements.
What changed
NLM registered a new clinical study (NCT07517770) on ClinicalTrials.gov for an AI-supported hybrid closed loop system designated AIDANET. The study aims to evaluate the system's safety and effectiveness in managing glucose levels for adults with Type 1 diabetes using an automated closed loop approach.
Healthcare providers and medical device manufacturers should note this trial as it represents continued development in AI-driven diabetes management technology. Study endpoints include CGM-based metrics and HbA1c reduction over a 12-week observation period in a single-arm design.
What to do next
- Monitor study results upon completion
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.